Kiel, Germany, December 2, 2025 — Tiakis Biotech has announced that it has successfully completed the required preclinical data package for Tiprelestat, enabling progression into a Phase II clinical trial for patients with pulmonary arterial hypertension (PAH). A pivotal six-month GLP toxicology study in rats demonstrated no adverse effects at doses representing a 20-fold safety margin over the intended therapeutic dose, marking a significant milestone as the company prepares for its ATHENA Phase II study scheduled for mid-2026. Tiprelestat is a novel biological therapy combining neutrophil elastase inhibition with BMPR2 amplification, designed to target the core inflammatory and vascular-remodelling mechanisms that characterize PAH. The compound has already been evaluated in five prior clinical studies involving more than 100 individuals, consistently showing a favourable safety profile. With the recent completion of its GLP toxicology program, tiakis is now positioned to advance Tiprelestat into mid-stage clinical evaluation for a life-threatening and underserved rare disease.
Science Significance
Pulmonary arterial hypertension is driven by escalating vascular resistance, endothelial dysfunction, chronic inflammation and progressive vascular remodelling. Existing treatments largely focus on symptomatic control and vasodilation, offering only partial relief without adequately addressing the underlying cellular mechanisms. Tiprelestat’s dual-action mechanism represents an important scientific advancement: by inhibiting neutrophil elastase, it reduces tissue injury and inflammation, while by amplifying BMPR2 activity, it helps restore vascular stability and function. The combination of these two modes of action positions Tiprelestat as a potential disease-modifying therapy, capable of influencing the biological drivers of PAH rather than simply managing symptoms.
Regulatory Significance
Completion of the GLP toxicology package satisfies a critical requirement for regulatory agencies when evaluating the transition of an investigational therapy into Phase II clinical testing. tiakis has previously received scientific guidance on its clinical development plan, including study endpoints and trial design for the ATHENA Phase II program. With safety margins established and preclinical data validated, the company is now prepared to finalize the submissions required for regulatory approval to initiate the trial. This milestone underscores tiakis’s commitment to meeting rigorous regulatory standards for biological therapeutics.
Business Significance
Advertisement
Advancing Tiprelestat into Phase II considerably strengthens tiakis Biotech’s pipeline and enhances its visibility within the rare-disease and cardiovascular-therapeutics landscape. PAH is an area of high unmet need, with few effective long-term treatments and significant commercial potential for a therapy with true disease-modifying capability. The strong toxicology results and prior human safety data may increase the attractiveness of Tiprelestat to investors, strategic partners and potential collaborators in the pharmaceutical sector. As a first-in-class, mechanism-driven therapy, it has the potential to secure orphan-drug incentives, extended market exclusivity and a competitive commercial profile.
Patients’ Significance
For individuals living with PAH, the emergence of Tiprelestat represents hope for a more effective therapeutic option that may alter the course of their disease. PAH often leads to reduced exercise capacity, severe shortness of breath, declining quality of life, and shortened lifespan. A therapy capable of reducing vascular damage, restoring endothelial function and halting disease progression could profoundly improve patient outcomes. If the upcoming Phase II trial confirms both safety and clinical benefit, Tiprelestat may offer a new pathway toward stabilizing or reversing a condition that currently has limited therapeutic choices.
Policy Significance
The advancement of Tiprelestat aligns with broader policy efforts to expand treatment options for rare and life-threatening diseases. As healthcare systems face rising burdens from chronic cardiopulmonary conditions, novel disease-modifying therapies could reduce hospitalizations, lower long-term care requirements and improve overall survival. The progress of Tiprelestat highlights the importance of continued investment, supportive regulatory frameworks and international collaboration in advancing therapies for rare diseases with significant public health implications.
With a validated preclinical safety profile, strong mechanistic rationale and supportive historical human data, Tiprelestat is now positioned to enter an important new phase of development for pulmonary arterial hypertension. tiakis Biotech’s commitment to advancing this dual-mechanism therapeutic marks a promising step forward in addressing a devastating rare disease. As the ATHENA Phase II trial approaches, expectations are building for a therapy that could reshape PAH management and offer new hope for patients worldwide.
Source: Tiakis Biotech press release
